

Technology appraisal (TA)			
Technology appraisal (TA)	Date of TA Release	Adherence of local formulary to NICE	
		Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2020-21			
TA688 - Selective internal radiation therapies for treating hepatocellular carcinoma	31/03/2021	N/A	Not classified as a drug treatment
TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	31/03/2021	Yes	
TA686 - Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)	31/03/2021	No	Terminated appraisal
TA685 - Anakinra for treating Still's disease	31/03/2021	Yes	
TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease	17/03/2021	No	Not applicable to CWFT - Not commissioned - Being challenged by Commissioning Pharmacist
TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer	10/03/2021	Yes	
TA682 - Erenumab for preventing migraine	10/03/2021	Yes	
TA681 - Baricitinib for treating moderate to severe atopic dermatitis	03/03/2021	Yes	
TA680 - Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma	03/03/2021	Yes	
TA679 - Dapagliflozin for treating chronic heart failure with reduced ejection fraction	24/02/2021	Yes	
TA678 - Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)	24/02/2021	No	Terminated appraisal
TA677 - Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma	24/02/2021	N/A	Not classified as a drug treatment
TA676 - Filgotinib for treating moderate to severe rheumatoid arthritis	24/02/2021	Yes	
TA675 - Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)	17/02/2021	No	Terminated appraisal
TA674 - Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)	17/02/2021	No	Terminated appraisal
TA673 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	17/02/2021	No	Not applicable to CWFT - Not commissioned
TA672 - Brodalumab for treating wet age-related macular degeneration	03/02/2021	Yes	
TA671 - Mepolizumab for treating severe eosinophilic asthma	03/02/2021	No	Not applicable to CWFT - Not commissioned
TA670 - Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor	27/01/2021	Yes	
TA669 - Trifluridine-tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies	27/01/2021	No	Not recommended
TA668 - Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer	06/01/2021	Yes	
TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura	16/12/2020	No	Not applicable to CWFT - Not commissioned
TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma	16/12/2020	No	Not applicable to CWFT - Not commissioned
TA665 - Upadacitinib for treating severe rheumatoid arthritis	09/12/2020	Yes	
TA664 - Liraglutide for managing overweight and obesity	09/12/2020	Yes	
TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia	09/12/2020	Yes	
TA662 - Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)	25/11/2020	No	Terminated appraisal
TA661 - Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma	25/11/2020	No	Not applicable to CWFT - Not commissioned
TA660 - Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer	25/11/2020	Yes	
TA659 - Galcanezumab for preventing migraine	18/11/2020	Yes	
TA658 - Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma	18/11/2020	Yes	
TA657 - Carfilzomib for previously treated multiple myeloma	18/11/2020	Yes	
TA656 - Siponimod for treating secondary progressive multiple sclerosis	18/11/2020	Yes	
TA655 - Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy	21/10/2020	Yes	
TA654 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer	14/10/2020	Yes	
TA653 - Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer	14/10/2020	Yes	
TA652 - Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)	07/10/2020	No	Terminated appraisal
TA651 - Naldemedine for treating opioid-induced constipation	30/09/2020	Yes	

TA650 - Pembrolizumab with axitinib for untreated advanced renal cell carcinoma	30/09/2020	No	Not recommended
TA649 - Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma	23/09/2020	Yes	
TA648 - Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)	09/09/2020	No	Terminated appraisal
TA647 - Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)	09/09/2020	No	Terminated appraisal
TA646 - Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)	09/09/2020	No	Terminated appraisal
TA645 - Avelumab with axitinib for untreated advanced renal cell carcinoma	02/09/2020	No	Not applicable to CWFT - Not commissioned
TA644 - Entrectinib for treating NTRK fusion-positive solid tumours	12/08/2020	Yes	
TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer	12/08/2020	Yes	
TA642 - Gilteritinib for treating relapsed or refractory acute myeloid leukaemia	12/08/2020	Yes	
TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma	12/08/2020	Yes	
TA640 - Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant	12/08/2020	No	Not applicable to CWFT - Not commissioned
TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer	01/07/2020	Yes	
TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	01/07/2020	Yes	
TA637 - Ranibizumab for treating diabetic retinopathy (terminated appraisal)	30/06/2020	No	Terminated appraisal
TA636 - Eculizumab for treating refractory myasthenia gravis (terminated appraisal)	30/06/2020	No	Terminated appraisal
TA635 - Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)	30/06/2020	No	Terminated appraisal
TA634 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)	30/06/2020	No	Terminated appraisal
TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	24/06/2020	Yes	
TA633 - Ustekinumab for treating moderately to severely active ulcerative colitis	17/06/2020	Yes	
TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer	10/06/2020	Yes	
TA631 - Fremanezumab for treating migraine	03/06/2020	Yes	
TA630 - Larotrectinib for treating NTRK fusion-positive solid tumours	27/05/2020	Yes	
TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab	13/05/2020	Yes	
TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer	13/05/2020	Yes	
TA627 - Lenalidomide with rituximab for previously treated follicular lymphoma	07/04/2020	Yes	